Free
Education  |   August 2001
A Double-blind, Randomized Comparison of IV Lorazepam versus  Midazolam for Sedation of ICU Patients via  a Pharmacologic Model
Author Affiliations & Notes
  • Juliana Barr, M.D.
    *
  • Katayoun Zomorodi, Ph.D.
  • Edward J. Bertaccini, M.D.
    *
  • Steven L. Shafer, M.D.
  • Eran Geller, M.S., M.D.
    §
  • * Staff Anesthesiologist, VA Palo Alto Health Care System, and Assistant Professor of Anesthesiology, Stanford University. † Research Associate, Department of Anesthesia, Stanford University, and Staff Scientist, Clinical Pharmacology, Alza Corporation, Palo Alto, California. ‡ Staff Anesthesiologist, VA Palo Alto Health Care System; Professor of Anesthesiology, Stanford University; and Vice President, Product Development, Pharsight Corporation, Mountain View, California. § Director, Medical-Surgical Intensive Care Unit, VA Palo Alto Health Care System, and Professor of Anesthesiology, Stanford University.
  • Received from the Department of Anesthesia, Stanford University School of Medicine, Stanford, California, and the Palo Alto VA Health Care System, Palo Alto, California.
Article Information
Education
Education   |   August 2001
A Double-blind, Randomized Comparison of IV Lorazepam versus  Midazolam for Sedation of ICU Patients via  a Pharmacologic Model
Anesthesiology 8 2001, Vol.95, 286-298. doi:
Anesthesiology 8 2001, Vol.95, 286-298. doi:
ArticlePlus
Click on the links below to access all the ArticlePlus for this article.
Please note that ArticlePlus files may launch a viewer application outside of your web browser.
PATIENTS undergoing major surgical procedures who require postoperative intubation and mechanical ventilation typically have a significant degree of anxiety and pain. 1 Sedative and analgesic agents are frequently administered to these patients in the intensive care unit (ICU) to prevent the cardiopulmonary and psychological complications associated with pain and anxiety. 2,3 Midazolam and lorazepam are the most commonly used benzodiazepines for ICU sedation. 4 Midazolam is a water-soluble, short-acting benzodiazepine that is rapidly metabolized by the liver via  the cytochrome P450 enzyme system to active (1- and 4-hydroxymidazolam) and inactive metabolites. The active metabolites of midazolam are subsequently conjugated by hepatic glucuronidation and excreted by the kidneys. 5 Lorazepam is a long-acting benzodiazepine that is metabolized by hepatic glucuronidation to inactive metabolites that are cleared by kidneys. 6 
The pharmacokinetics of midazolam administered as continuous intravenous infusions for sedation in ICU patients differ significantly from the pharmacokinetics of intravenously administered midazolam in healthy individuals. 7–10 To date, the pharmacokinetics of intravenous lorazepam have only been studied in healthy subjects being given single bolus injections or short (i.e.,  60 min) infusions of lorazepam. 11–13 Studies of lorazepam in critically ill patients have been limited to assessing the dose–response relationship of lorazepam for ICU sedation. 14,15 
Lorazepam has recently been advocated as an economic alternative to midazolam for long-term sedation of ICU patients. 16 In the absence of a comprehensive pharmacologic analysis of lorazepam, there are currently no scientifically validated dosing guidelines for the use of lorazepam infusions in the ICU, making it difficult for clinicians to rationally titrate lorazepam in critically ill patients. The purposes of the current study are as follows: (1) to characterize and compare the pharmacokinetic profiles of midazolam and lorazepam in adult surgical ICU patients; (2) to correlate midazolam and lorazepam plasma concentrations with the depth of sedation and the degree of amnesia achieved in these patients; (3) to compare the ease of titration and the recovery profile of the two agents; and (4) to develop rational dosing guidelines for sedation with lorazepam infusions based on the clinical pharmacology of lorazepam in surgical ICU patients.
Materials and Methods
Study Design
After Institutional Review Board (Administrative Panel on Human Subjects in Medical Research, Stanford University School of Medicine, Stanford, CA) approval, written informed consent was obtained from 24 adult patients (age range, 18–85 yr) requiring postoperative intubation and mechanical ventilation in the ICU for up to 72 h after elective surgery at the VA Palo Alto Health Care System (Palo Alto, CA). Individuals were excluded from the study if they had significant hepatic, renal, or neurologic impairment; a recent history of long-term benzodiazepine use or known substance abuse; or a known allergy to either drug. Subjects were given no benzodiazepines within 72 h before the start of the study.
All subjects were prospectively randomly assigned in a double-blinded fashion to be given either midazolam (Versed; Roche Pharmaceuticals, Inc., Nutley, NJ) or lorazepam (Ativan; Wyeth-Ayerst Laboratories, Philadelphia, PA) for postoperative sedation. Midazolam and lorazepam were administered intravenously to all subjects via  a target-controlled infusion (TCI) to achieve predefined levels of sedation. The TCI device consisted of an 80386-20 laptop computer (Everex, Inc., Fremont, CA), with an MS-DOS operating system (Microsoft, Inc., Redmond, WA) running STANPUMP software, 1connected via  serial interface to an intravenous infusion pump (Harvard Pump Model 22; Harvard Apparatus, Inc., South Natick, MA). For the first 13 subjects, STANPUMP targeted plasma study drug concentrations using previously derived pharmacokinetic models for midazolam 17 and lorazepam. 11 In the remaining 11 subjects, STANPUMP targeted plasma study drug concentrations using revised pharmacokinetic models for midazolam and lorazepam derived from the initial 13 subjects to achieve more accurate plasma levels. Postoperative analgesia was provided using either intravenous fentanyl (Sublimaze; Janssen Pharmaceuticals, Inc., Titusville, NJ) administered via  a TCI (using pharmacokinetic parameters for fentanyl previously described by Shafer et al  . 18), or epidural infusions of morphine (Astramorph; Astra-Zeneca Pharmaceuticals, Westborough, MA) and bupivacaine (Marcaine; Sanofi Winthrop, New York, NY). Intraoperative opioids were limited to intravenous fentanyl (3–5 μg/kg) or epidural morphine (≤10-mg bolus). All other intraoperative anesthetic and therapeutic agents were administered to subjects according to standard anesthetic techniques.
Postoperatively, subjects were transferred from the operating room directly to the ICU, where they remained intubated and mechanically ventilated and were allowed to regain consciousness. Their depth of sedation was evaluated using a modified version of the Ramsay Sedation Scale (table 1). 19 When subjects had emerged from anesthesia to a sedation score (SS) of 2 or 3, postoperative analgesia was instituted with either an intravenous fentanyl infusion (set to a target plasma concentration of 1.5 ng/ml) or epidural morphine and bupivacaine infusions. Once adequate analgesia was achieved (analgesic medication titrated to a pain-free state), sedation was initiated in a blinded fashion with either a midazolam or lorazepam infusion set to a target plasma concentration of 50 ng/ml. Then the target plasma concentration of the study sedative was titrated up by 25–50 ng/ml every 30 min until SS was equal to 4. If the SS was greater than 4 at any time, the target plasma concentration was decreased by 50% and the subject was observed closely until SS was equal to 3 or 4; then the target plasma concentration was set to the sedative concentration predicted by the STANPUMP program at that time. If a subject became restless, the target plasma concentration of the study sedative was increased by 50 ng/ml or as needed until adequate sedation was achieved. The target plasma concentration required to sustain an SS of 3 or 4 was maintained for 12–72 h, or as long as sedation was clinically indicated. Both the sedative and fentanyl infusions were stopped when subjects were ready to be weaned from mechanical ventilation. If additional analgesia was required after discontinuation of the fentanyl infusion, small intravenous boluses of morphine (1–2 mg) were administered.
Table 1. Modified Ramsay Sedation Score 19 
Image not available
Table 1. Modified Ramsay Sedation Score 19 
×
Data Acquisition and Processing
Heart rate, arterial blood pressure (systolic, diastolic, and mean), central venous pressure, and SS were recorded, and arterial blood samples for the benzodiazepine assay were collected from each subject at the following times: (1) at baseline postoperatively before starting the sedative infusion in the ICU; (2) immediately before and at 5, 15, 30, 45, 60, and 120 min after each change in the sedative target plasma concentration; and (3) immediately before and at 5, 15, 30, 45, and 60 min, then at 2, 4, 6, 12, 18, and 24 h after discontinuation of the sedative infusion. Arterial blood samples were collected in 5-ml heparinized glass tubes and immediately placed on ice. Samples were centrifuged at 3,000 rpm for 10 min, and the plasma fraction was separated into polypropylene storage tubes and stored at −20°C until assayed. Plasma benzodiazepine analyses were performed at Stanford University (Stanford, CA) using high-performance liquid chromatography with a limit of quantitation of 16 ng/ml for both the midazolam and lorazepam assays. (A detailed description of the benzodiazepine assay used can be found in Appendix 1 in the Web Enhancement.)
Adequacy of Sedation and Amnesia Assessments
Nurses taking care of each subject were asked at the end of their 8- to 12-h shift to assess the ease of titration of sedation and the adequacy of sedation on a visual analog scale. The investigator (Dr. Geller) completed a similar sedation assessment for each subject within 24 h after discontinuation of the study drug. Both the nurses and the investigator were blinded as to the sedative used in each case. Twenty-four hours after extubation, each subject was asked to complete a questionnaire to assess his or her recall of unpleasant experiences (e.g.,  pain, anxiety, intubation, mechanical ventilation) during the period of sedation.
Postsedation amnesia was assessed by showing subjects a series of pictures depicting simple objects at different intervals after discontinuation of the study sedative. As soon as a subject was able to initially identify an object, he or she was shown drawings of this object plus additional objects 3, 6, 12, 24, and 36 h later. If subjects recognized a particular object, they were asked at later times if they recalled the drawing shown to them earlier. Once subjects recalled three consecutive drawings previously shown to them, they were no longer considered amnestic. At that point, subjects were shown a composite of drawings and asked to identify what drawings had been shown to them previously. Dundee and George 20 have previously validated this method of recognition and recall testing after administration of benzodiazepines.
Statistical Analyses
Members of the Department of Anesthesia, Stanford University School of Medicine, performed all statistical analyses. Summary results are expressed as mean ± SD unless otherwise noted. P  values were derived using analysis of variance F  testing. A value of P  = 0.05 was considered to be statistically significant in this case. Subjective sedation assessments by subjects being given either lorazepam or midazolam were compared with a chi-square analysis. A value of P  = 0.05 was considered to be statistically significant.
Multiple nonlinear logistic regression analyses were performed to characterize the pharmacokinetic and pharmacodynamic models for both lorazepam and midazolam. Model performance was assessed both numerically and graphically in both groups. (A detailed summary of the pharmacokinetic and pharmacodynamic analyses can be found in Appendix 2 in the Web Enhancement.) The newly derived pharmacokinetic and pharmacodynamic models for lorazepam and midazolam were integrated to construct dosing regimens and estimate emergence times for light and deep sedation with either agent.
Results
Demographics
Table 2summarizes the demographics of the 24 subjects enrolled in the study. Ten subjects were given midazolam, and 14 subjects were given lorazepam. All subjects underwent either major vascular, urologic, or general surgical procedures. Both groups were similar in terms of their height, weight, body surface area, and body mass index. The lorazepam subjects were older, on average, than the midazolam subjects. Although there was a statistically significant difference in the Apache II scores between the two groups, this difference was not considered to be clinically significant. 21 
Table 2. Demographic Characteristics of Subjects Studied (n = 24)
Image not available
Table 2. Demographic Characteristics of Subjects Studied (n = 24)
×
Three subjects being given lorazepam developed acute agitation, delirium, tachycardia, and hypertension after discontinuation of the benzodiazepine infusion. This was attributed to acute alcohol withdrawal rather than benzodiazepine withdrawal because all three subjects were subsequently found to have an extensive history of alcohol use preoperatively (which they had denied at the time of enrollment), and all had been given benzodiazepine infusions for less than 48 h. A fourth lorazepam subject had a mechanical failure of the fentanyl drug infusion system during the study. All four of these subjects were replaced in a blinded fashion. When the randomization code was unblinded, all four subjects had been randomly replaced with lorazepam subjects, a finding that was not considered relevant. These four substituted lorazepam subjects were included in the pharmacokinetic analyses but excluded from the pharmacodynamic analyses because their sedation scores were potentially confounded. In one midazolam subject, a failure of the drug infusion system was diagnosed only after the study was closed and unblinded. As a result, this midazolam subject was not replaced and was subsequently excluded from both the pharmacokinetic and pharmacodynamic analyses.
Benzodiazepine sedation was initiated in all subjects within 2 h of their arrival to the ICU from the operating room. Four subjects in each group were given postoperative analgesia via  epidural morphine and bupivicaine, and the remaining subjects were given intravenous fentanyl via  TCI. No significant hemodynamic differences were observed between the midazolam and lorazepam groups during study drug administration. All subjects had extubation and were discharged from the ICU in stable condition. One subject who developed an increased serum bilirubin level after pancreatic tumor resection died 3 weeks after the end of the study from causes unrelated to the subject’s participation in the study.
Table 3summarizes the study drug infusion profiles for all 24 subjects. There were significant differences in the duration of infusion and the average infusion rates between the two groups. The lorazepam group was given infusions for longer periods, on average (36.9 h), than the midazolam group (15 h). This difference was primarily attributable to three lorazepam subjects who were given lorazepam infusions for greater than 60 h. The average infusion rates for each group were 0.91 and 2.54 mg/h for lorazepam and midazolam, respectively.
Table 3. Drug Infusion Data (n = 24)
Image not available
Table 3. Drug Infusion Data (n = 24)
×
Pharmacokinetics and Pharmacodynamics
Twenty-three subjects (9 midazolam subjects and 14 lorazepam subjects) were included in the final pharmacokinetic analyses. Eighteen subjects (nine midazolam subjects and nine lorazepam subjects) were included in the pharmacodynamic and sedation analyses. In addition to excluding the four lorazepam subjects who were initially replaced, a fifth lorazepam subject was also excluded from the pharmacodynamic and sedation analyses because sedation assessments were not interpretable.
The original and revised pharmacokinetic models for lorazepam and midazolam are summarized in table 4. A two-compartment, mixed-effects model best describes the data for both drugs. Including age and weight as covariates into the estimates for central volume of distribution (V1) and metabolic clearance (Cl1) significantly improved the performance of the midazolam model. The accuracy of the lorazepam model was not improved with the addition of any covariates. The revised models for both agents differed significantly from the original models, both numerically and in terms of their accuracy in predicting plasma benzodiazepine concentrations. (A detailed comparison of the original and revised pharmacokinetic models for both agents is summarized in Appendix 3 in the Web Enhancement.)
Table 4. Original versus Revised Pharmacokinetic Models for Lorazepam and Midazolam
Image not available
Table 4. Original versus Revised Pharmacokinetic Models for Lorazepam and Midazolam
×
Table 5summarizes the results of the sequential pharmacodynamic analyses using the naïve pooled data approach (the mixed-effects modeling approach did not adequately describe the pharmacodynamic data). Model H best described the data both numerically (i.e.,  having the smallest objective function and the highest percentage of correct and close sedation score predictions) and graphically based on the basic model:MATHwhere P(Sedation ≥ ss) = probability of level of sedation ≥ SS (2–6); C = plasma benzodiazepine concentration; C50,ss= plasma benzodiazepine concentration where P(Sedation ≥ ss) = 50%; and γ= slope of probability curve. (For a more complete description of the various pharmacodynamic models tested, see appendix table 1 in the Web Enhancement.)
Table 5. Pharmacodynamic Parameters Estimated for All Models*(n = 18)
Image not available
Table 5. Pharmacodynamic Parameters Estimated for All Models*(n = 18)
×
Model H estimated the potency of lorazepam to be twice that of midazolam, which corresponds to the observed midazolam:lorazepam concentration ratio of 1.8 (table 6). Therefore, estimated C50,ssvalues (where SS ≥ 2, 3, 4, 5, and 6) for lorazepam are half those of midazolam (34, 51, 104, 152, and 188 ng/ml for lorazepam vs.  68, 101, 208, 304, and 375 ng/ml for midazolam, respectively). In the presence of fentanyl, the effective C50,ssvalues for both lorazepam and midazolam are decreased by 18% (i.e.,  all C50,ssvalues are multiplied by a fentanyl effect parameter of 0.82). This is consistent with the observed effect of fentanyl on benzodiazepine sedation, where subjects being given intravenous fentanyl for analgesia were more deeply sedated at comparable benzodiazepine concentrations than subjects being given epidural analgesia in both groups (fig. 1). The dissipating effects of surgery and anesthesia also reduced the amount of benzodiazepine sedation initially required. This “virtual drug” effect corresponds to an initial plasma midazolam concentration of 159 ng/ml, with an elimination half-life of 12.4 h. Model H predicted that the age of the individual significantly influences the effects of midazolam and lorazepam sedation as well. Within the age range of the population studied, the estimated C50,ssvalues for both lorazepam and midazolam were decreased by 18% for every 10 yr of age. There was a significant difference in the estimated slopes of the probability curves for lorazepam and midazolam. The slope of the midazolam curves is steeper (i.e.,  larger γ value) than that of the lorazepam curves, resulting in a faster predicted onset and offset of sedation with midazolam than with lorazepam at equipotent concentrations (fig. 2).
Table 6. Observed Benzodiazepine Plasma Concentrations (SS = 2–5)
Image not available
Table 6. Observed Benzodiazepine Plasma Concentrations (SS = 2–5)
×
Fig. 1. Sedation score versus  measured plasma benzodiazepine concentrations for lorazepam (A  ) and midazolam (B  ) in the presence and absence of intravenous fentanyl.
Fig. 1. Sedation score versus 
	measured plasma benzodiazepine concentrations for lorazepam (A 
	) and midazolam (B 
	) in the presence and absence of intravenous fentanyl.
Fig. 1. Sedation score versus  measured plasma benzodiazepine concentrations for lorazepam (A  ) and midazolam (B  ) in the presence and absence of intravenous fentanyl.
×
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus  normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus 
	normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus  normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
×
Adequacy of Sedation and Amnesia
Subjects in both groups were effectively sedated throughout the study with minimal agitation (< 1%). However, there were significant differences in the observed sedation patterns between lorazepam and midazolam subjects (table 7). The number of initial titrations required to achieve optimal sedation (SS = 3 or 4) were similar in both groups, although the median time to achieve this level of sedation was much longer in the lorazepam group (335 min) than in the midazolam group (5.5 min). This difference is attributable in part to study design. To preserve study blinding, both midazolam and lorazepam were administered to subjects with an initial target plasma concentration of 50 ng/ml, which was increased every 30 min as needed to achieve SS = 4. At this initial target concentration, in the presence of fentanyl or resolving sedative effects of surgery and anesthesia, lorazepam subjects tended to be initially oversedated, requiring subsequent decreases in the target plasma benzodiazepine concentration and delaying the time required to achieve optimal sedation. During the maintenance period of sedation, subjects in the lorazepam group were optimally sedated (SS = 3 or 4) only 49% of the time versus  69% of the time for midazolam subjects (fig. 3). Lorazepam subjects were more deeply sedated (i.e.,  SS = 5 or 6) more often (47%) than midazolam subjects (22%). These depth of sedation differences between lorazepam and midazolam subjects were statistically and clinically significant (P  = 0.0001). There were also significant differences in emergence times between the two groups after discontinuation of the benzodiazepine infusion (table 7). Lorazepam subjects emerged from sedation more slowly and had extubation much later than midazolam subjects (i.e.,  8.7 vs.  3 h and 21.2 vs.  5.4 h , respectively). Nurses caring for subjects and blinded to the study drug administered found both drugs to be comparable in terms of ease of titration and adequacy of sedation (table 7). In contrast, the investigator, who was also blinded to the study drug, thought that midazolam was easier to titrate and provided more adequate sedation than lorazepam.
Table 7. Observed Benzodiazepine Sedation Patterns (n = 18)
Image not available
Table 7. Observed Benzodiazepine Sedation Patterns (n = 18)
×
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
×
Figures 4A and Bcompare the relative amnestic effects of lorazepam to midazolam in the subjects studied. Figure 4Ademonstrates that the observed amnestic effect of lorazepam was significantly greater than that of midazolam throughout the postinfusion period. At 24 h after infusion, the amnestic effect of midazolam had resolved in all subjects, whereas approximately 50% of the lorazepam subjects continued to exhibit impaired recall; at 36 h after infusion, 30% of the lorazepam group still demonstrated impaired recall. Figure 4Bshows the relationship between the incidence of recall and plasma benzodiazepine concentrations. The observed C50,ssvalues for lorazepam and midazolam-induced amnesia were approximately 6 and 25 ng/ml, respectively, giving lorazepam a relative amnestic potency of 4 compared with midazolam. There were no significant differences in the subjective recall assessments by subjects, and the majority of subjects in both groups had no unpleasant recall of their experiences in the ICU.
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A  ) versus  time during the postinfusion period and (B  ) versus  plasma benzodiazepine concentration.
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A 
	) versus 
	time during the postinfusion period and (B 
	) versus 
	plasma benzodiazepine concentration.
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A  ) versus  time during the postinfusion period and (B  ) versus  plasma benzodiazepine concentration.
×
Discussion
Both midazolam and lorazepam are commonly administered as continuous intravenous infusions for sedation of intubated ICU patients. Although the pharmacology of intravenous midazolam infusions for ICU sedation has been well characterized, the pharmacology of lorazepam infusions in this setting has not been previously established. The lack of pharmacologic data for intravenous lorazepam infusions in critically ill patients has made it difficult to adequately compare the sedative effects of lorazepam and midazolam infusions or to create valid dosing guidelines for lorazepam in these patients. The results of the current study demonstrate that there are substantial pharmacokinetic and pharmacodynamic differences between midazolam and lorazepam which have significant clinical and drug dosing implications in ICU patients.
Pharmacokinetics
The pharmacokinetics of midazolam in the current study were best described by a two-compartment model with age and weight as covariates on V1and weight as a covariate on Cl1(table 4). The midazolam model described the data with minimal bias and a high degree of accuracy, although there was significant interindividual variability, especially during the postinfusion phase (see appendix figures 1A, 1B, 2A, and 2B in the Web Enhancement). This variability is probably attributable to the greater variability in age and weight in the midazolam group, as reflected by their influence as covariates in the pharmacokinetic model derived for midazolam. The values derived for V1, Cl1, and peripheral clearance (Cl2) for midazolam in the current study were similar to those of the model of Zomorodi et al.  17 for midazolam used in the initial phase of the current study (see appendix table 2 in the Web Enhancement). The presence of a large third peripheral compartment in the model of Zomorodi et al  ., 17 which is absent from the midazolam model derived in the current study, is most likely the result of differences in study populations, drug dosing, and study design. In the trial of Zomorodi et al.  , 17 subjects were given larger doses of midazolam than were subjects in the current study (i.e.,  48.4 vs.  37 mg), and part of the dose was administered intraoperatively during cardiopulmonary bypass surgery. The effect of cardiopulmonary bypass on midazolam kinetics is to increase the V1and decrease the Cl1, as a result of hemodilution, alterations in protein binding, and decreases in liver blood flow during cardiopulmonary bypass surgery. 22–24 
The pharmacokinetics of lorazepam in the current study were also described by a two-compartment model, albeit without covariates. This revised model for lorazepam described the data with much less bias and a higher degree of accuracy than the original model for lorazepam derived by Greenblatt et al.  11 (table 4). The pharmacokinetic parameters estimated for lorazepam in the current study differed significantly from those described by Greenblatt et al.  11 (see appendix table 2 in the Web Enhancement). Both models for lorazepam are two-compartment models with similar estimates for the central V1and the Cl1, but the peripheral volume of clearance (V2) estimated in the current study was 2.5 times larger and the estimated Cl2was 40% less than estimated by Greenblatt et al.  11 The larger estimated V2is most likely attributable to the larger doses of lorazepam administered to subjects in the current study than in the study by Greenblatt et al.  11 (i.e.,  31.7 vs.  2–4 mg). Larger lorazepam doses allow for a more accurate estimate of V2(and hence the total volume of distribution) because plasma lorazepam concentrations remain above the limits of detection of the lorazepam assay for longer periods after decreases in the lorazepam infusion rate. The slower Cl2estimated for lorazepam in the current study may be explained by differences in tissue blood flow and protein binding of lorazepam between healthy and critically ill patients. The larger V1, together with the slower Cl2estimated for lorazepam, results in a much longer elimination half-life for lorazepam (952 min) than predicted by model of Greenblatt et al.  11 (736 min). As a result of these model differences, the model of Greenblatt et al.  11 tends to overestimate lorazepam plasma levels during the infusion period and underestimate them during the postinfusion period compared with the revised lorazepam model (see appendix figures 1C, 1D, 2C, and 2D in the Web Enhancement).
The results of the current study demonstrate significant pharmacokinetic differences between lorazepam and midazolam. Lorazepam has a larger estimated V1and a smaller estimated V2than midazolam, although the total volume of distribution is similar for both agents (see appendix table 2 in the Web Enhancement). This difference may be explained by the greater lipid solubility of midazolam, with greater redistribution into peripheral tissues compared with lorazepam. 6 This may also account for the slower Cl2of midazolam. The estimated Cl1for midazolam is 2.5 times the estimated Cl1of lorazepam. This may be explained by differences in the hepatic metabolism of these two drugs; the hepatic glucuronidation of lorazepam occurs much more slowly than the oxidative hydroxylation of midazolam by the cytochrome P450 enzyme system in the liver. 25,26 The slower metabolic clearance of lorazepam accounts for its longer elimination half-life as compared with midazolam (i.e.,  952 min for lorazepam vs.  572 min for midazolam). These pharmacokinetic differences account for some of the differences in the observed onset and offset of sedation between these two agents.
Pharmacodynamics
The pharmacodynamics of lorazepam and midazolam sedation were best described by Model H, which accounts for differences in potency and onset and offset times of sedation between the two agents. Model H also includes the effects of age, fentanyl administration, and residual effects of surgery and anesthesia on benzodiazepine sedation (table 5). This model predicts with 76% accuracy that an approximate level of sedation would result from a corresponding benzodiazepine plasma concentration at steady state. The model also predicts that the potency of lorazepam is twice that of midazolam. This is consistent with the average observed midazolam:lorazepam concentration ratio of 1.8 (table 6) and the differences in the observed lorazepam and midazolam concentrations at the time of extubation (17.39 ng/ml for lorazepam vs.  38.21 ng/ml for midazolam;table 7). Previously, the potency ratio for lorazepam to midazolam had not been described in critically ill patients. Model H also accounts for the more rapid onset and offset of sedation with midazolam than with lorazepam, which is independent of their pharmacokinetic differences. This is reflected in the larger γ value for midazolam (table 5) which represents a steeper probability curve and a more rapid transition between different levels of sedation for midazolam than for lorazepam as the benzodiazepine concentration varies over time (fig. 2).
Age was found to be a significant covariate of benzodiazepine sedation in the current study independent of its effects on pharmacokinetics. Older subjects required much lower benzodiazepine plasma concentrations to achieve comparable levels of sedation as compared with younger patients. This is consistent with the clinical observation that elderly patients appear to be more sensitive to the effects of benzodiazepines. Although most of the subjects in the current study were greater than 60 yr of age, there appeared to be an inverse linear relationship between age and C50,ssacross the spectrum of sedation, with an 18% decrease in the benzodiazepine C50,ssvalue for each additional 10 yr of age. It is important not to extrapolate this result to much younger individuals, whose age is not reflected in the current study population. Otherwise, one might conclude that a 30-yr-old patient would require 3 × 18%, or 54%, higher benzodiazepine levels than a 60-yr-old individual to achieve similar levels of sedation.
The model predicts that the estimated C50,ssvalues for both agents are decreased by 18% in the presence of fentanyl, which is consistent with the study observation that subjects being given intravenous fentanyl in both groups were sedated at much lower plasma benzodiazepine concentrations (fig. 1). This also accounts for the fact that the observed plasma benzodiazepine concentrations at SS = 2–5 (table 6) were less than the predicted C50,ssvalues at each level of sedation (table 5). The measured benzodiazepine plasma concentrations included subjects being given intravenous fentanyl in both groups, whereas the C50,ssvalues estimated by the model are independent of the effects of fentanyl. Because fentanyl levels were not measured in the current study, the effect of fentanyl in this model is a binary all-or-none effect. This may be attributable to the inaccuracy of using predicted rather than measured fentanyl concentrations in determining the model. The pharmacokinetic model used to administer fentanyl to subjects in the current study was derived from a different patient population 18 (i.e,  healthy individuals being given short-term fentanyl infusions) and may not accurately predict fentanyl concentrations in our subjects. As an alternative, the fentanyl concentration-effect curve may be sufficiently steep that the effect of fentanyl on sedation is an all-or-none binary phenomenon.
Model H also accounts for the synergistic effect between benzodiazepine sedation and the resolving sedative effects of surgery and anesthesia during the immediate postoperative period. This “virtual drug” effect was described in a previous pharmacodynamic model for midazolam in patients undergoing coronary artery bypass grafting who were being given midazolam for postoperative sedation. 27 In the present study, the virtual drug effect has an initial sedative effect equivalent to a midazolam plasma concentration of 159 ng/ml, which decreases exponentially over time with an elimination half-life of 12.4 h (table 5). The model predicts that after approximately 37 h (i.e.,  three virtual drug half-lives), the virtual drug effect on sedation is minimal and the sedative effects of benzodiazepines remain relatively constant, assuming steady-state fentanyl requirements.
Dosing Regimens for Benzodiazepine Sedation
By integrating the derived pharmacokinetic and pharmacodynamic models for lorazepam and midazolam, we can simulate continuous intravenous infusions of midazolam or lorazepam in similar patients and predict the resulting patterns of sedation and emergence with a high degree of accuracy. Tables 8 and 9summarize midazolam and lorazepam sedation regimens required for postoperative sedation of a 71-yr-old, 70-kg male ICU patient. These are based on constant-rate infusion regimens adjusted over time to maintain either light (SS = 3) or deep (S = 5) levels of sedation with or without intravenous infusions of fentanyl (i.e.,  ≤ 200 μg/h) for analgesia. The benzodiazepine concentrations used to define depth of sedation and emergence in each case are based on the modes (i.e.,  peaks) of the probability curves for discrete sedation scores (i.e.,  SS = 1, 2, 3, . . .6) rather than the estimated C50,ssvalues because the distribution of the discrete probability curves are asymmetric, making the modes a more accurate prediction of sedation than the C50,ssvalues (fig. 5). Bolus doses and subsequent infusion rates for each benzodiazepine regimen are listed for infusions lasting up to 72 h, at which point near–steady-state infusion rates and emergence times have been achieved for each regimen, assuming that constant levels of sedation are maintained. Emergence time from sedation is defined as the time it takes for the patient to emerge to SS = 2 after discontinuation of the benzodiazepine infusion. At this level of sedation, a patient is easily arousable and able to follow commands and may be potentially extubated if appropriate. The emergence times listed at each point in time represent the predicted emergence time if the benzodiazepine infusion were discontinued at that moment. The infusion regimens that include fentanyl assume that the fentanyl infusions are started immediately upon admission to the ICU and are continued after discontinuation of the benzodiazepine infusion for postoperative analgesia.
Table 8. Representative Dosing Guidelines for Continuous Intravenous Infusions of Midazolam for Intensive Care Unit Sedation*
Image not available
Table 8. Representative Dosing Guidelines for Continuous Intravenous Infusions of Midazolam for Intensive Care Unit Sedation*
×
Table 9. Representative Dosing Guidelines for Continuous Intravenous Infusions of Lorazepam for Intensive Care Unit Sedation*
Image not available
Table 9. Representative Dosing Guidelines for Continuous Intravenous Infusions of Lorazepam for Intensive Care Unit Sedation*
×
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
×
The predicted emergence times from different benzodiazepine sedation regimens differ considerably, depending on the depth of sedation maintained, the duration of infusion, and the agent used. For the first 24 h postoperatively, the residual sedative effects of surgery and anesthesia heavily influence the emergence time. As a consequence of this virtual drug effect, initial boluses of benzodiazepines are not required for light sedation, and the start of the benzodiazepine infusion may be delayed for 2–3 h postoperatively, until the patient emerges from anesthesia and surgery. To maintain deep levels of sedation, initial bolus doses of benzodiazepines are required, with higher benzodiazepine infusion rates for the first 3–6 h postoperatively to induce and maintain deep levels of sedation. By 12–24 h, the virtual drug effect has diminished and the benzodiazepine levels have increased to the point that steady-state benzodiazepine infusion rates are achieved for both agents. By 36 h, the virtual drug effect has essentially resolved and emergence time from sedation primarily becomes a function of declining benzodiazepine levels.
The rate at which benzodiazepine plasma levels decrease after discontinuation of the infusion is a function of the benzodiazepine pharmacokinetics, the duration of the infusion, and the benzodiazepine level at the time the infusion is terminated. Figure 6shows the predicted time required for lorazepam and midazolam plasma concentrations to decrease by 43 and 75% as a function of the infusion duration at steady-state sedation. A 43% decrease in benzodiazepine levels would be required for patients to emerge from light sedation (i.e.,  SS = 3 → 2), while a 75% decrease would be required for them to emerge from deep sedation (i.e.,  SS = 5 → 2). The predicted emergence time from sedation with lorazepam is much longer than that of midazolam, regardless of the infusion duration or depth of sedation. In this example, emergence time from light sedation with midazolam infusions lasting longer than 12 h is 3–5 h versus  an emergence time of 10–12 h for light sedation with lorazepam infusions of similar duration (tables 8 and 9). Patients who are deeply sedated with either agent have much greater emergence times, even with short-term (i.e.,  < 24 h) benzodiazepine infusions. In this example, emergence time from deep sedation with midazolam infusions lasting longer than 12 h is approximately 15 h versus  an emergence time of approximately 30 h after deep sedation with lorazepam for comparable periods. Figure 7compares the emergence times from light and deep sedation after a 72-h TCI of either midazolam or lorazepam. These results are consistent with the predicted emergence times listed in tables 8 and 9for constant-rate infusions, as well as the emergence times observed in the current study. The average observed emergence time from light to moderate sedation (i.e.,  SS = 3 or 4 → 2) was 3 h in the midazolam group and 9 h in the lorazepam group (table 7).
Fig. 6. Predicted time required for (A  ) a 43% decrease and (B  ) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
Fig. 6. Predicted time required for (A 
	) a 43% decrease and (B 
	) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
Fig. 6. Predicted time required for (A  ) a 43% decrease and (B  ) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
×
Fig. 7. Predicted emergence times after (A  ) light (SS = 3) and (B  ) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
Fig. 7. Predicted emergence times after (A 
	) light (SS = 3) and (B 
	) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
Fig. 7. Predicted emergence times after (A  ) light (SS = 3) and (B  ) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
×
The synergistic sedative effect of fentanyl with benzodiazepine sedation results in reduced benzodiazepine requirements and infusion rates. Fentanyl may also affect emergence time, although this influence is not reflected in the simulated infusion regimens (tables 8 and 9) because the fentanyl infusions were continued after termination of the benzodiazepine infusion. Discontinuing the fentanyl infusion concurrently with the benzodiazepine infusion shortens the maximum emergence time for both agents (i.e.,  from 15 h to 12 h after deep sedation with midazolam and from 31 h to 26 h after deep sedation with lorazepam).
These emergence times from sedation with midazolam and lorazepam are in contrast to the sedation emergence times observed in previous studies comparing midazolam and lorazepam infusions in ICU patients. In the study reported by Pohlman et al.  , 15 subjects being given midazolam infusions took longer  to emerge from sedation than lorazepam subjects (i.e.,  30.3 h for midazolam vs.  4.4 h for lorazepam). 15 The longer midazolam emergence times observed by Pohlman et al  . 15 are probably related to the relatively larger drug doses administered in the midazolam group. In that study, the average total dose of midazolam administered was 23 versus  5 mg/kg in the lorazepam group. In the absence of measured plasma benzodiazepine concentrations or any attempt to construct a pharmacokinetic–pharmacodynamic model to compensate for study bias, it is difficult to conclude that midazolam and lorazepam subjects in the study reported by Pohlman et al  . 15 were comparably sedated. Thus, it is impossible to compare emergence times between the two groups in the current study.
Sedative versus  Amnestic Effects of Midazolam and Lorazepam
There were significant differences between the observed amnestic potency of midazolam and lorazepam in the current study that could not be explained by their sedative effects alone. The amnestic potency of lorazepam to midazolam was 4 (fig. 4), compared with a sedative potency of 2 (table 5). The greater amnestic potency of lorazepam, together with its longer duration of action, resulted in significant delays in the resolution of amnesia in the lorazepam group (> 36 h) compared with the midazolam group (< 24 h). This has clinically significant implications for management of patients after their lorazepam infusion has been discontinued; although patients are awake and are able to follow commands, they might not be able remember relevant conversations and events for several days.
Subjective assessments by the subjects studied and the nurses caring for them showed that the quality of sedation and anxiolysis achieved with lorazepam and midazolam were similar in the current study (table 7). This is consistent with the results of the study of Cernaianu et al.  , 14 who reported that nurses caring for ICU patients who were sedated with either lorazepam or midazolam infusions found that the quality of sedation was similar for both agents. The blinded investigator in the current study thought it was easier to titrate midazolam infusions to a desired level of sedation than lorazepam infusions. This is, perhaps, explained by the study design, which required a greater number of initial titrations (made primarily by the investigator) in the lorazepam group to achieve optimal sedation.
Conclusion
Both lorazepam and midazolam are safe and effective sedative agents when administered as continuous intravenous infusions for postoperative sedation of surgical ICU patients. The results of the current study demonstrate that there are significant differences in the clinical pharmacology of lorazepam and midazolam, which have significant clinical implications in these patients. Lorazepam is more potent and has a longer duration of action than midazolam. The longer duration of sedative effect may lead to significant delays in extubation and discharge of ICU patients who have been given even short-term infusions of lorazepam for sedation.
Maintaining patients at deep levels of sedation with either agent may delay emergence from sedation, extubation, and ICU discharge. Surgical ICU patients initially have lower benzodiazepine requirements because of the residual sedative effects of surgery and anesthesia. This effect is negligible beyond the first postoperative day. Administering fentanyl infusions for analgesia in conjunction with benzodiazepines reduces the amount of benzodiazepine sedation required and hastens the emergence from sedation in patients when the two drugs are discontinued simultaneously.
The current study demonstrates that mathematical models derived from critically ill patients can be used to accurately predict benzodiazepine plasma concentrations and resulting sedation levels over time in these patients. This enables us to develop rational dosing guidelines for postoperative sedation of surgical ICU patients with either agent, taking into account the synergistic sedative effects of resolving anesthesia and intravenous fentanyl administered for postoperative analgesia. This minimizes the effect of study design and differences in drug administration regimens in interpreting the observed differences between two study groups.
The authors thank James Trudell, Ph.D., Professor of Chemistry in Anesthesia, Department of Anesthesia, Stanford University School of Medicine, Stanford, California, for his efforts in developing and performing the midazolam and lorazepam assays. The authors also thank the intensive care unit nursing staff and the surgical staff at the VA Palo Alto Health Care System, Palo Alto, California, for all their assistance and suggestions during the current study.
References
Berger I, Waldhorn RE: Analgesia, sedation and paralysis in the intensive care unit. Am Fam Physician 1995; 51: 166–72Berger, I Waldhorn, RE
Burns AM, Shelly MP, Park GR: The use of sedative agents in critically ill patients. Drugs 1992; 43: 507–15Burns, AM Shelly, MP Park, GR
Mendel PR, White PF: Sedation of the critically ill patient. Int Anesthesiol Clin 1993; 31: 185–200Mendel, PR White, PF
Dasta JF, Fuhrman TM, McCandles C: Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit. Crit Care Med 1994; 22: 974–80Dasta, JF Fuhrman, TM McCandles, C
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM: Use of midazolam as a human cytochrome P450 3A probe: I. vitro–in vivo correlations in liver transplant patients. In J Pharmacol Exp Ther 1994; 271: 549–56Thummel, KE Shen, DD Podoll, TD Kunze, KL Trager, WF Hartwell, PS Raisys, VA Marsh, CL McVicar, JP Barr, DM
Greenblatt DJ: Sedation: Intravenous benzodiazepines in critical care medicine, The Pharmacological Approach to the Critically Ill Patient, 3rd edition. Edited by Chernow B. Baltimore, Williams & Wilkins, 1994, pp 321–6
Driessen JJ, Dirksen MS, Rutten JM, Santman F, van Egmond J, Vree TB: Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. Acta Anaesthesiol Scand 1989; 33: 116–21Driessen, JJ Dirksen, MS Rutten, JM Santman, F van Egmond, J Vree, TB
Driessen JJ, Vree TB, Guelen PJ: The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 1991; 42: 149–55Driessen, JJ Vree, TB Guelen, PJ
Shafer A, Doze VA, White PF: Pharmacokinetic variability of midazolam infusions in critically ill patients. Crit Care Med 1990; 18: 1039–41Shafer, A Doze, VA White, PF
Oldenhof H, de Jong M, Steenhoek A, Janknegt R: Clinical pharmacokinetics of midazolam in intensive care patients: A wide interpatient variability? Clin Pharmacol Ther 1988; 43: 263–9Oldenhof, H de Jong, M Steenhoek, A Janknegt, R
Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS, Harmatz JS, Allen MD, Werner A, Woo E: Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57–63Greenblatt, DJ Shader, RI Franke, K MacLaughlin, DS Harmatz, JS Allen, MD Werner, A Woo, E
Greenblatt DJ, Divoll M, Harmatz JS, Shader RI: Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71: 248–52Greenblatt, DJ Divoll, M Harmatz, JS Shader, RI
Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, Shader RI: Kinetic and dynamic study of intravenous lorazepam: Comparison with intravenous diazepam. J Pharmacol Exp Ther 1989; 250: 134–40Greenblatt, DJ Ehrenberg, BL Gunderman, J Scavone, JM Tai, NT Harmatz, JS Shader, RI
Cernaianu AC, DelRossi AJ, Flum DR, Vassilidze TV, Ross SE, Cilley JH, Grosso MA, Boysen PG: Lorazepam and midazolam in the intensive care unit: A randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. Crit Care Med 1996; 24: 222–8Cernaianu, AC DelRossi, AJ Flum, DR Vassilidze, TV Ross, SE Cilley, JH Grosso, MA Boysen, PG
Pohlman AS, Simpson KP, Hall JB: Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: A prospective, randomized study. Crit Care Med 1994; 22: 1241–7Pohlman, AS Simpson, KP Hall, JB
Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA, Schein RM, Spevetz A, Stone JR: Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: An executive summary—Society of Critical Care Medicine. Crit Care Med 1995; 23: 1596–600Shapiro, BA Warren, J Egol, AB Greenbaum, DM Jacobi, J Nasraway, SA Schein, RM Spevetz, A Stone, JR
Zomorodi K, Donner A, Somma J, Barr J, Sladen R, Ramsay J, Geller E, Shafer SL: Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. A nesthesiology 1998; 89: 1418–29Zomorodi, K Donner, A Somma, J Barr, J Sladen, R Ramsay, J Geller, E Shafer, SL
Shafer SL, Varvel JR, Aziz N, Scott JC: Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. A nesthesiology 1990; 73: 1091–102Shafer, SL Varvel, JR Aziz, N Scott, JC
Ramsay MA, Savege TM, Simpson BR, Goodwin R: Controlled sedation with alphaxalone-alphadolone. Br Med J 1974; 2: 656–9Ramsay, MA Savege, TM Simpson, BR Goodwin, R
Dundee JW, George KA: The amnesic action of diazepam, flunitrazepam and lorazepam in man. Acta Anaesthesiol Belg 1976; 27 (suppl): 3–11Dundee, JW George, KA
Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818–29Knaus, WA Draper, EA Wagner, DP Zimmerman, JE
Kanto J, Himberg JJ, Heikkila H, Arola M, Jalonen J, Laakosnen V: Midazolam kinetics before, during, and after cardiopulmonary bypass surgery. Int J Clin Pharmacol Res 1985; 5: 123–6Kanto, J Himberg, JJ Heikkila, H Arola, M Jalonen, J Laakosnen, V
Mathews HM, Carson IW, Lyons SM, Orr IA, Collier PS, Howard PJ, Dundee JW: A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61: 302–7Mathews, HM Carson, IW Lyons, SM Orr, IA Collier, PS Howard, PJ Dundee, JW
Wood M: Pharmacokinetics and principles of drug infusions in cardiac patients, Cardiac Anesthesia. Edited by Kaplan JA, Reich DL, Konstadt SN. Philadelphia, WB Saunders, 1999, pp 657–85
Ameer B, Greenblatt DJ: Lorazepam: A review of its clinical pharmacological properties and therapeutic uses. Drugs 1981; 21: 162–200Ameer, B Greenblatt, DJ
Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ: Midazolam: Pharmacology and uses. A nesthesiology 1985; 62: 310–24Reves, JG Fragen, RJ Vinik, HR Greenblatt, DJ
Somma J, Donner A, Zomorodi K, Sladen R, Ramsay J, Geller E, Shafer SL: Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery. A nesthesiology 1998; 89: 1430–43Somma, J Donner, A Zomorodi, K Sladen, R Ramsay, J Geller, E Shafer, SL
Fig. 1. Sedation score versus  measured plasma benzodiazepine concentrations for lorazepam (A  ) and midazolam (B  ) in the presence and absence of intravenous fentanyl.
Fig. 1. Sedation score versus 
	measured plasma benzodiazepine concentrations for lorazepam (A 
	) and midazolam (B 
	) in the presence and absence of intravenous fentanyl.
Fig. 1. Sedation score versus  measured plasma benzodiazepine concentrations for lorazepam (A  ) and midazolam (B  ) in the presence and absence of intravenous fentanyl.
×
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus  normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus 
	normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
Fig. 2. Midazolam and lorazepam probability curves for sedation score (SS) ≥ 4 versus  normalized plasma benzodiazepine concentration for model H. Normalized plasma benzodiazepine concentrations are based on the predicted plasma benzodiazepine concentrations derived from the population pharmacokinetic model, which are then normalized by their respective C50,ssand virtual drug concentration values.
×
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
Fig. 3. Incidence of a sedation score of 1–6 in lorazepam and midazolam subjects during the benzodiazepine infusion period.
×
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A  ) versus  time during the postinfusion period and (B  ) versus  plasma benzodiazepine concentration.
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A 
	) versus 
	time during the postinfusion period and (B 
	) versus 
	plasma benzodiazepine concentration.
Fig. 4. Incidence of lorazepam and midazolam subjects recalling an object (A  ) versus  time during the postinfusion period and (B  ) versus  plasma benzodiazepine concentration.
×
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
Fig. 5. Probability curves for discrete sedation scores (SS = 1, 2, 3, . . . 6).
×
Fig. 6. Predicted time required for (A  ) a 43% decrease and (B  ) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
Fig. 6. Predicted time required for (A 
	) a 43% decrease and (B 
	) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
Fig. 6. Predicted time required for (A  ) a 43% decrease and (B  ) a 75% decrease in plasma benzodiazepine concentration as a function of the duration of the benzodiazepine infusion. This corresponds to the benzodiazepine concentration change required to emerge from light and deep sedation, respectively.
×
Fig. 7. Predicted emergence times after (A  ) light (SS = 3) and (B  ) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
Fig. 7. Predicted emergence times after (A 
	) light (SS = 3) and (B 
	) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
Fig. 7. Predicted emergence times after (A  ) light (SS = 3) and (B  ) deep (SS = 5) sedation with target-controlled infusions of either midazolam or lorazepam for 72 h. VD = virtual drug effect.
×
Table 1. Modified Ramsay Sedation Score 19 
Image not available
Table 1. Modified Ramsay Sedation Score 19 
×
Table 2. Demographic Characteristics of Subjects Studied (n = 24)
Image not available
Table 2. Demographic Characteristics of Subjects Studied (n = 24)
×
Table 3. Drug Infusion Data (n = 24)
Image not available
Table 3. Drug Infusion Data (n = 24)
×
Table 4. Original versus Revised Pharmacokinetic Models for Lorazepam and Midazolam
Image not available
Table 4. Original versus Revised Pharmacokinetic Models for Lorazepam and Midazolam
×
Table 5. Pharmacodynamic Parameters Estimated for All Models*(n = 18)
Image not available
Table 5. Pharmacodynamic Parameters Estimated for All Models*(n = 18)
×
Table 6. Observed Benzodiazepine Plasma Concentrations (SS = 2–5)
Image not available
Table 6. Observed Benzodiazepine Plasma Concentrations (SS = 2–5)
×
Table 7. Observed Benzodiazepine Sedation Patterns (n = 18)
Image not available
Table 7. Observed Benzodiazepine Sedation Patterns (n = 18)
×
Table 8. Representative Dosing Guidelines for Continuous Intravenous Infusions of Midazolam for Intensive Care Unit Sedation*
Image not available
Table 8. Representative Dosing Guidelines for Continuous Intravenous Infusions of Midazolam for Intensive Care Unit Sedation*
×
Table 9. Representative Dosing Guidelines for Continuous Intravenous Infusions of Lorazepam for Intensive Care Unit Sedation*
Image not available
Table 9. Representative Dosing Guidelines for Continuous Intravenous Infusions of Lorazepam for Intensive Care Unit Sedation*
×